Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia.
Sima Jeha(St. Jude Children's Research Hospital), Peter G. Steinherz(Memorial Sloan Kettering Cancer Center), Susan R. Rheingold(Children's Hospital of Philadelphia), Paul S. Gaynon(University of Southern California), Richard Kadota(Roswell Park Comprehensive Cancer Center), Manuel Castro‐Fernández(Hospital Universitario de Valme), Bassem I. Razzouk(Peyton Manning Children’s Hospital at St.Vincent), Michael Rytting(The University of Texas MD Anderson Cancer Center), R.J. Arceci(Johns Hopkins University), Steven Weitman(Children's Hospital of Orange County), Violet Shen(Ruhr University Bochum), Lori Luchtman‐Jones(Cincinnati Children's Hospital Medical Center)
Cited by 11
Related Papers
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|920
Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update
|Journal of Clinical Oncology|2011|839
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
|Journal of Clinical Oncology|2001|825
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
|Cancer Cell|2012|722
Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2000|599